A double-blind, placebo-controlled, multicenter study of cerebrolysin for alzheimer's disease

Journal of the American Geriatrics Society

Volumn 48, Issue 12, 2000, Pages 1566-1571

  Bae, Chul Young ^a   Cho, Choo Yon ^b   Cho, Kyunghee ^c   Oh, Byoung Hoon ^d   Choi, Kyoung Gyu ^e   Lee, Hong Soo ^e   Jung, Seung Pil ^c   Kim, Dae Hyun ^f   Lee, Sangdo ^f   Choi, Gyu Dong ^g   Cho, Hangsuk ^h   Lee, Hotaek ^a  

^a Pochon CHA Medical University   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Department of Family Medicine and Geriatrics Ilsan Hospital ^*  (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f Keimyung University   (South Korea)

^g SolarLight Ltd   (South Korea)

^h Kwandong University College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; cerebrolysin; clinical trial

Indexed keywords

AMINO ACID; CEREBROLYSIN; NOOTROPIC AGENT; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; GERIATRIC ASSESSMENT; HOSPITALIZATION; HUMAN; MALE; MENTAL HEALTH; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; AMINO ACIDS; DOUBLE-BLIND METHOD; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NOOTROPIC AGENTS; PLACEBOS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034540880     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2000.tb03865.x     Document Type: Conference Paper

References (33)

1. Knapp MJ, Knopman DS, Solomon PR, et al,. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
2. Farlow M, Gracon SI, Hershey LA, et al,. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-2529.
3. Rogers SL, Farlow MR, Doody RS, et al,. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
4. Rogers SL, Friedhoff LT,. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multi-center open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
5. Cummings JL, Cyrus PA, Bieber F, et al,. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998; 50: 1214-1221.
6. Morris JC, Cyrus PA, Orazem J, et al,. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-1230.
7. Hefti F, Schneider LS,. Nerve growth factor and Alzheimer's disease. Clin Neuropharmacol 1991; 14: 62-76.
8. Tuszynski MH, Gage FH,. Potential use of neurotrophic agents in the treatment of neurodegenerative disorders. Acta Neurobiol Ek 1990; 50: 323-332.
9. Ruther E, Ritter R, Apecechea M, et al,. Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry 1994; 27: 32-40.
10. Rainer M, Brunbauer M, Dunky A, et al,. Therapeutic results with Cerebrolysin in the treatment of dementia. Wien med Wschr 1997; 147: 426-431.
11. Valouskova V, Francis-Turner L,. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: Short-term study. Neurosci Lett 1996; 202: 193-196.
12. Piswanger A, Paier B, Windisch M,. Modulation of protein synthesis in a cell-free system from rat brain by Cerebrolysin during development and aging. Amino Acids 1990; 651-657.
13. Basky A, Wojtowicz JN,. Actions of organ derived preparations on synaptic transmission in the hippocampus. Neurobiol Aging 1992; 13 (suppl 1): 128.
14. Shimazu S, Iwamoto N, Akasako A, et al,. The neurotrophic and brain protein effect of Cerebrolysin. Neurobiol Aging 1992; 13 (suppl 1): 50.
15. Albrecht E, Hingel S, Crailsheim K, et al,. The effects of Cerebrolysin on the vitality and sprouting of neurons from cerebral hemispheres and from the brain stem of chicken embryos in vitro. Neurobiol Aging 1992; 13 (suppl 1): 127.
16. Windisch M, Albrecht E, Eggenreich B, et al,. Neurotrophic effects of the nootropic drug Cerebrolysin-A summary. Neurobiol Aging 1992; 13 (suppl 1): 133.
17. Akai F, Hiruma S, Sato T, et al,. Neurotrophic factor-like effect of FPF 1070 on septal cholinergic neurons after transection of fimbria-fornix in the rat brain. Histol Histopathoi 1992; 7: 213-221.
18. Kofler B, Erhart C, Erhart P, et al,. A multidimensional approach in testing nootropic drug effects (Cerebrolysin). Arch Gerontol Geriatr 1990; 10: 129-140.
19. Kofler B, Erhart C, Erhart P, et al,. Zur therapeutischen Wirksamkeit von Cerebrolysin. Psychology 1989; 15: 29-33.
20. McKhann G, Drachman D, Filstein M, et al,. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34: 939-944.
21. Folstein MF, Folstein SE, McHugh, Mini Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
22. Rosen WG, Terry RD, Fuld P, et al,. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486-488.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Rev Ed. Washington, DC: American Psychiatric Association, 1994.
24. Rogen WG, Mohs RC, Davis K,. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
25. Guy W,. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services, 1976, pp 218-222.
26. Mohs RC, Davis BM, Johns CA, et al,. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142: 28-33.
27. Yesavage JA, Brink TL, Rose TL, et al,. Development and validation of a geriatric depression rating scale: A preliminary report. J Psych Res 1983; 17: 27.
28. Katz S, Ford A, Moskowitz R, et al,. The index of ADL: A standardized measure of biological and psychological function. JAMA 1963; 185: 914-919.
29. Lawton MP, Brody EM,. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-185.
30. Kanovski S, Fischhof P, Hiersemsnzel R,. Wirksamkeitsnachweis von nootropika am beispiel von nimodipin-ein beitrag entwicklung geeigneter klinischer prufmodelle. Z Gerontopsychol und-psychiatric 1988; 1: 35-44.
31. Kanovski S, Fischer PK, Einsler R Grobe,. Efficacy of xantinolnicotinate in patients with dementia. Pharmacopsychiatry 1990; 23: 118-124.
32. Kneczevics S, Mubrin Z, Spilich G, et al,. Long-term treatment of SDAT patients with pyritinol. In:, Maurer K, Riederer P, Beckmann H, eds. Alzheimer's Disease. Epidemiology, Neurobiology, Neurochemistry, and Clinics. Vienna: Springer-Verlag, 1990, pp 565-574.
33. Galasko D, Benneett D, Sano M,. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11 (suppl 2): S33-S39.